Loading your page…
Diabetology
By Pavlina A. Andreeva-Gateva, Milen Hristov, Dragomira Nikolaeva Nikolova and 3 others.
Background/Objectives: This study aimed to assess the effect of tirzepatide on systemic inflammation in a diabetic neuropathy (DN) model in mice.
Ward brings these articles into the same app as your cards and questions. One free account for Ward, Suture, Osler and Prognia.
Type 1 diabetes was induced with streptozotocin 180 mg/kg i.p. One month later, we injected two doses of tirzepatide (5 or 15 mcg/kg BW s.c. e3d) over the next 4 weeks, then performed a battery of neurological tests and measured blood cytokines with the Simple Plex® platform CE-IVD version. Data were compared with naïve controls with or without diabetes induction.
Tirzepatide treatment failed to improve both glycemia and neuropathic behavior post-streptozotocin treatment. Higher-dose tirzepatide-treated mice had significantly decreased grip strength (p = 0.013) and higher cold (p = 0.04) and mechanical (p < 0.001) sensitivity, despite substantially lower systemic inflammation, as assessed by TNF-α and IL-6. An exploratory composite inflammatory index (ECII) derived from IL-6 and TNF-α showed statistically significantly lower systemic inflammation in the group treated with a higher tirzepatide dose vs. the treatment-naïve control (p < 0.05), the diabetic group (p < 0.05), and the diabetic group treated with lower-dose tirzepatide (p < 0.05).
Tirzepatide failed to improve DN in a streptozotocin-induced murine nonobese model of type 1 diabetes, although it substantially decreased systemic inflammation. Testing tirzepatide for potential protection against DN in non-streptozotocin-based DN animal models is warranted.
Published in Diabetology. The abstract is shown as published and remains the work of its authors; read the full article at the source.
Prognia lists this article for reference and education. It is not medical advice. Always read the original and follow current guidelines and local protocols before acting on it.
